Vycellix

Vycellix, Inc., headquartered at the Moffitt Cancer Center in Tampa, Florida, is an exploratory company focused on immunotherapy. Its mission is to fundamentally address current prevailing challenges in the field of cell and gene-based therapies. The company is dedicated to developing proprietary approaches for cell-based immunotherapy products and improving patient outcomes.Vycellix's scientific discoveries, combined with small molecules and RNA modulators, address current limitations in cell and gene therapy, including the need to accelerate production, reduce costs, ensure end-cell viability and persistence, and improve patient outcomes. The company’s innovative solutions offer the potential for significant process optimization: cell reprogramming; enhanced cell potency; and improved cell expansion. Additionally, the company is leveraging its assets to develop an early pipeline of multi-faceted next-generation NK cell therapies targeting hematologic malignancies and solid tumors, including its ReOpt-NK™ (retargeted NK cell) therapy.The company’s products were discovered by scientists at the world-renowned Karolinska Institute (KI) in Stockholm, Sweden. KI is globally recognized as the Nobel Assembly that awards the Nobel Prize in Physiology or Medicine.